Around 40% of available marketed drugs are poorly bioavailable or soluble, and about 90% of New Chemical Entities are known for their low solubility and permeability Lexaria’s patented DehydraTECH(TM) technology offers a solution by improving how APIs (active pharmaceutical ingredients) enter the bloodstream DehydraTECH achieves this by bypassing first-pass-liver metabolism By doing so, Lexaria is … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics”
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reporting additional results from its human clinical study HYPER-H21-2. The study was designed to evaluate the company’s proprietary DehydraTECH(TM)-processed cannabidiol (“CBD”) and its effectiveness in the treatment of hypertension. Results confirm the substance’s ability to reduce arterial stiffness and indicate potential broader applications beyond … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction”
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that it is participating in the Benzinga Global Small Cap Conference. The premier two-day virtual event is scheduled for Dec. 8–9, 2021. The company encourages shareholders and other interested parties to attend the event and learn more about investment opportunities within the global … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference”
Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD”
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently conducted a study on canines in collaboration with an independent testing laboratory. The analysis evaluated nicotine benzoate and polacrilex plasma levels in 40 anesthetized male beagle dogs comparing Lexaria’s recently developed, advanced DehydraTECH 2.0 nicotine formulation to concentration-matched controls. The dogs’ blood samples were taken every few minutes over … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study”
Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension HYPER-H21-4 will build on successes witnessed in initial human hypertension studies The company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications”
Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets The 2022 program will continue to focus on the company’s patented DehydraTECH drug delivery … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes”
Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and it’s most ambitious yet This study builds on the HYPER-H21-1 and HYPER-H21-2 findings, as well as the HYPER-H21-3 study that is set to begin dosing in mid-November 2021 Lexaria’s goal is to pursue regulatory approval for its proprietary DehydraTECH-CBD for potential use … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4”
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs for 2022. According to the update, the studies mentioned in the announcement represent only a fraction of Lexaria’s 2022 work programs. “Calendar 2022 will continue to see significant milestones in utilizing … Continue reading “CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes”
Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to FDA-approved seizure drug, Epidiolex The study will also compare DehydraTECH-CBD to generic CBD EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3 2022 Lexaria received new … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio”
